Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL

25 Jan 2021

Abstract excerpt

In chronic lymphocytic leukemia (CLL), the lymph node (LN) microenvironment delivers critical survival signals by inducing the expression of anti-apoptotic Bcl-2 members Bcl-XL, Bfl-1, and Mcl-1, resulting in apoptosis blockade. We determined previously that resistance against various drugs, among which is the clinically applied BH3 mimetic venetoclax, is dominated by upregulation of the anti-apoptotic regulator...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to Chronic Lymphocytic Leukemia Research
Share to Immunodeficiency and Autoimmune Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33495554
DOI: 10.1038/s41418-020-00692-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLLPMID 33495554Read ↗

NF-κB as a therapeutic target in chronic lymphocytic leukemiaSemantic proximity Read ↗

NF-kB and the CLL microenvironmentSemantic proximity Read ↗

NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions.Semantic proximity Read ↗

When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype.Semantic proximity Read ↗

Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell MalignanciesSemantic proximity Read ↗

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapySemantic proximity Read ↗

Targeting BCL-2 overexpression in various human malignancies through NF-κB inhibition by the proteasome inhibitor bortezomibSemantic proximity Read ↗

The potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaSemantic proximity Read ↗

Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering.Semantic proximity Read ↗

Targeting anti‐apoptotic BCL 2 family proteins in haematological malignancies – from pathogenesis to treatmentSemantic proximity Read ↗

Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclaxSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.